BioCryst Pharmaceuticals, Inc. (BCRX)
7.295
-0.20
(-2.73%)
USD |
NASDAQ |
Nov 18, 16:00
7.34
+0.04
(+0.62%)
After-Hours: 20:00
BioCryst Pharmaceuticals Total Return Level : 7.50 for Nov. 17, 2026
Total Return Level Chart
Historical Total Return Level Data
| Date | Value |
|---|---|
| November 17, 2026 | 7.50 |
| November 16, 2026 | 7.45 |
| November 13, 2026 | 7.61 |
| November 12, 2026 | 7.68 |
| November 11, 2026 | 7.65 |
| November 10, 2026 | 7.53 |
| November 09, 2026 | 7.63 |
| November 06, 2026 | 7.69 |
| November 05, 2026 | 7.63 |
| November 04, 2026 | 8.24 |
| November 03, 2026 | 8.57 |
| November 02, 2026 | 8.245 |
| October 30, 2026 | 8.47 |
| October 29, 2026 | 8.52 |
| October 28, 2026 | 8.37 |
| October 27, 2026 | 8.10 |
| October 26, 2026 | 7.88 |
| October 23, 2026 | 7.65 |
| October 22, 2026 | 7.78 |
| October 21, 2026 | 7.75 |
| October 20, 2026 | 7.94 |
| October 19, 2026 | 8.07 |
| October 16, 2026 | 7.79 |
| October 15, 2026 | 8.02 |
| October 14, 2026 | 8.05 |
| Date | Value |
|---|---|
| October 13, 2026 | 8.07 |
| October 12, 2026 | 8.36 |
| October 09, 2026 | 8.55 |
| October 08, 2026 | 8.29 |
| October 07, 2026 | 8.40 |
| October 06, 2026 | 7.95 |
| October 05, 2026 | 8.10 |
| October 02, 2026 | 8.17 |
| October 01, 2026 | 8.12 |
| September 30, 2026 | 8.33 |
| September 29, 2026 | 8.27 |
| September 28, 2026 | 8.47 |
| September 25, 2026 | 8.59 |
| September 24, 2026 | 8.52 |
| September 23, 2026 | 8.57 |
| September 22, 2026 | 8.78 |
| September 21, 2026 | 8.76 |
| September 18, 2026 | 8.68 |
| September 17, 2026 | 8.70 |
| September 16, 2026 | 8.43 |
| September 15, 2026 | 8.16 |
| September 14, 2026 | 8.23 |
| September 11, 2026 | 8.12 |
| September 10, 2026 | 8.29 |
| September 09, 2026 | 8.805 |
Total Return Level Definition
The total return level allows investors to view the performance of a security inclusive of both price appreciation and dividends/distributions. Total return level is seen as the most accurate calculation that produces returns consistent with most other sources.
Total Return Level Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Return Level Benchmarks
| Halozyme Therapeutics, Inc. | 95.97 |
| Neurocrine Biosciences, Inc. | 165.92 |
| Agenus, Inc. | 6.21 |
| Amgen, Inc. | 685.72 |
| Anika Therapeutics, Inc. | 12.85 |